It shouldn't hurt that the drugmaker beat third-quarter estimates and raised its profit guidance for all of 2018.
Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.
The Swiss drugmaker will pay $2.1 billion for Endocyte, justifying the Nasdaq-listed biotech's pivot to prostate treatment last year.
Cancer affects all of us. But the Damon Runyon Cancer Research Foundation has invested $355 million (and counting) in research to fight it. We spent time with its incoming CEO to hear about her journey and how immunotherapies are taking the lead.
Follow the experts. These biotech stocks have Wall Street's best analysts getting bullish.
Innate Immunotherapeutics of Australia is the biopharmaceutical company at the center of the insider trading charges leveled against New York Rep. Chris Collins.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.